Clinical Use of U-500 Regular Insulin: Review and Meta-Analysis
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
The use of U-500 regular insulin (U-500R) to treat diabetic patients with severe insulin resistance has increased. In this review, we performed a meta-analysis of PubMed studies reporting the use of U-500R to evaluate the effects of U-500R on hemoglobin A1c (HbA1c), body weight, and total daily insulin dose (TDD). These studies included 310 patients using U-500R as multiple daily injections (MDI) and 55 patients using U-500R via continuous subcutaneous insulin infusion (CSII). Overall, the use of U-500R as MDI resulted in a significant HbA1c reduction of 1.59%, a significant weight gain of 4.38 kg, and a significant increase in TDD by 51.9 units. The use of U-500R via CSII resulted in a similarly significant HbA1c reduction of 1.64% but a nonsignificant weight gain and a nonsignificant change in TDD. The use of U-500 regular insulin both as MDI and via CSII was not reported to be associated with severe hypoglycemia but was associated with an increase in patient satisfaction as well as in cost savings. Suggestions in initiating U-500R in the outpatient setting using U-500R in hospitalized patients are reviewed. In addition, precautions for avoiding prescription and patient errors are discussed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similarly, in persons with T2D who are treated with basal-bolus insulin therapy, adding a GLP-1 RA or switching to a fixed-ratio combination of a GLP-1 RA and a basal insulin or adding an SGLT2i1098 or pramlintide can serve as adjuncts to prandial insulin therapy to reduce postprandial hyperglycemia, A1C, and weight.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1098]
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Gupta, A., & Uribarri, J. (2016) · Hormone Research in Paediatrics · doi:10.1159/000444053 · Cited by 4,006
The Syndromes of Insulin Resistance and Acanthosis Nigricans: Insulin-Receptor Disorders in Man
Kahn, C. R., Flier, J. S., Bar, R. S., Archer, J. A., Gorden, P., Martin, M. M., & Roth, J. (1976) · New England Journal of Medicine · doi:10.1056/nejm197604012941401 · Cited by 1,106
Binder, C., Lauritzen, T., Faber, O., & Pramming, S. (1984) · Diabetes Care · doi:10.2337/diacare.7.2.188 · Cited by 341
Absorption of Injected Insulin: A Clinical‐Pharmacological Study
BINDER, C. (1969) · Acta Pharmacologica et Toxicologica · doi:10.1111/j.1600-0773.1969.tb03069.x · Cited by 287
Musso, C., Cochran, E., Moran, S. A., Skarulis, M. C., Oral, E. A., Taylor, S., & Gorden, P. (2004) · Medicine · doi:10.1097/01.md.0000133625.73570.54 · Cited by 264
Galloway, J. A., Spradlin, C. T., Nelson, R. L., Wentworth, S. M., Davidson, J. A., & Swarner, J. L. (1981) · Diabetes Care · doi:10.2337/diacare.4.3.366 · Cited by 226
ARIOGLU, E., ANDEWELT, A., DIABO, C., BELL, M., TAYLOR, S. I., & GORDEN, P. (2002) · Medicine · doi:10.1097/00005792-200203000-00001 · Cited by 223
Research works printed but not linked: 6
- Khan M, 2007, Diabetes., 569, P-1294
- Khan M, 2009, Diabetes., 58, PO-2333
- Garg R, 2004, Diabetologia., 47, A58
- Boldo A, 2011, Endocr Pract., 1
- Ziesmer AE, 2011, Endocr Pract., 1
- U.S. Food and Drug Administration., 2012, MAUDE Adverse Event Report.
Cited by
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Peters, A. L., Ahmann, A. J., Battelino, T., Evert, A., Hirsch, I. B., Murad, M. H., Winter, W. E., & Wolpert, H. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2534 · Cited by 250
“The only comparison in the literature is based on a loosely designed meta-analysis that compared U-500 by MDI vs CSII between studies, suggesting equal efficacy but less weight gain and less increase in insulin dose with CSII (56).”
MethodGrunberger, G., Abelseth, J. M., Bailey, T. S., Bode, B. W., Handelsman, Y., Hellman, R., Jovanovič, L., Lane, W. S., Raskin, P., Tamborlane, W. V., et al. (2014) · Endocrine Practice · doi:10.4158/ep14145.ps · Cited by 180
“14) after conversion to R U-500 insulin delivered by CSII (73).”
MethodInsulin Therapy for Type 2 Diabetes Mellitus
Wallia, A., & Molitch, M. E. (2014) · JAMA · doi:10.1001/jama.2014.5951 · Cited by 153
Treatment Approach to Patients With Severe Insulin Resistance
Church, T., & Haines, S. T. (2016) · Clinical Diabetes · doi:10.2337/diaclin.34.2.97 · Cited by 76
“The mean total daily insulin dose increased by 52 units (95% CI 20–84) (19).”
Background
Metadata
- Authors
- Reutrakul, S., Wroblewski, K., & Brown, R. L.
- Affiliations
- Rush University Medical Center (US)
- University of Chicago (US)
- Corresponding author
- Reutrakul, Sirimon
- Venue
- Journal of Diabetes Science and Technology
- Publisher
- SAGE Publications
- Published
- 2012-03
- Volume
- 6
- Issue
- 2
- Pages
- 412-420
- ISSN
- 1932-2968 (ISSN-L)
- PMC
- PMC3380787
- OpenAlex
- W2142265157
- Cited by
- 94
- References
- 38
- Citations by year
- 2026: 1 · 2024: 2 · 2023: 5 · 2022: 4 · 2021: 7 · 2020: 8 · 2019: 5 · 2018: 5 · 2017: 8 · 2016: 16 · 2015: 11 · 2014: 15 · 2013: 7
- FWCI
- 1.46
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of Diabetes Science and Technology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Center for Research Resources (UL1RR024999)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- insulin resistance, type 2 diabetes, glycemic control, HbA1c, weight gain, total daily insulin dose, multiple daily insulin injections, insulin pump therapy, hypoglycemia, patient satisfaction, cost reduction, prescribing errors, patient education
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Injections, Subcutaneous, Insulin, Insulin Infusion Systems, Insulin Resistance, Risk Factors, Biomarkers, Weight Gain, Drug Costs, Treatment Outcome, Cost Savings, Patient Satisfaction, Infusions, Subcutaneous
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical Use of U-500 Regular Insulin: Review and Meta-Analysis. https://app.cochat.ai/papers/10.1177/193229681200600229
- The paper
- Reutrakul, S., Wroblewski, K., & Brown, R. L. (2012). Clinical Use of U-500 Regular Insulin: Review and Meta-Analysis. Journal of Diabetes Science and Technology. https://doi.org/10.1177/193229681200600229
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.